Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR
Clinical trial NCT02691871 · UNKNOWN
Trial details
- NCT number
- NCT02691871
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-01
- Primary completion
- 2016-10-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.